Skip to content
2000
Volume 11, Issue 1
  • ISSN: 2667-3371
  • E-ISSN: 2667-338X

Abstract

Due to its ability to track drug interactions and their physiological effects on humans, pharmacovigilance is a vital component of the healthcare system. The ability to monitor and analyze medications for quality as well as identify and halt any unfavorable drug side effects makes pharmacovigilance a crucial component of modern technology. Drug safety data collection and coding, as well as case management reporting and submission, comprise case processing, which is the first step in pharmacovigilance. The Pharmacovigilance Programme of India was established in response to these advancements. India participates in the Uppsala Monitoring Centre system but contributes very little to the database itself. The objective of this research is to conduct a comprehensive analysis of the pharmacovigilance program in India and provide a succinct, current evaluation of the organization, taking into account its background and possible issues. The development of “A Pharmacovigilance Programme of India” mobile application was emphasized by the National Coordination Centre PvPI to India as a means of enhancing public health and encouraging prompt reporting of adverse drug reactions. With more and more cutting-edge veterinary medications entering the market, India needs a veterinary pharmacovigilance system. One of the most significant current responsibilities is demonstrating to the world that thousands of years-old Ayurveda Siddha Unani systems are safe and grounded in science.

Loading

Article metrics loading...

/content/journals/adctra/10.2174/0126673371363002250506053414
2025-03-12
2025-09-28
Loading full text...

Full text loading...

References

  1. PawarK.N. GoreR.T. PalekarS.R. A review on approval process and regulation of medical devices as per US FDA and CDSCO.Int. J. Drug Regul. Aff.2023111617010.22270/ijdra.v11i1.586
    [Google Scholar]
  2. RehanH.S. ChopraD. HolaniS.N. MishraR. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.Int. J. Risk Saf. Med.20142611810.3233/JRS‑14060824796346
    [Google Scholar]
  3. EvangelineL. Regulatory process and ethics for clinical trials in India (CDSCO).Pharma Innov.201764, Part C165
    [Google Scholar]
  4. BanerjeeP. Latest regulatory guidelines and the process of adr reporting in India.Indian J. Pharmaceut. Sci.2022102150160
    [Google Scholar]
  5. AivalliP.K. EliasM.A. PatiM.K. BhanuprakashS. MunegowdaC. ShroffZ.C. SrinivasP.N. Perceptions of the quality of generic medicines: implications for trust in public services within the local health system in Tumkur, India.BMJ Glob. Health20182Suppl. 3e00064410.1136/bmjgh‑2017‑00064429531844
    [Google Scholar]
  6. MoorS.E.G. TusubiraA.K. WoodD. AkitengA.R. GalushaD. Tessier-ShermanB. DonroeE.H. NgaruiyaC. RabinT.L. HawleyN.L. Armstrong-HoughM. NakiryaB.D. NugentR. KalyesubulaR. NalwaddaC. SsinabulyaI. SchwartzJ.I. Patient preferences for facility-based management of hypertension and diabetes in rural Uganda: A discrete choice experiment.BMJ Open2022127e05994910.1136/bmjopen‑2021‑05994935863829
    [Google Scholar]
/content/journals/adctra/10.2174/0126673371363002250506053414
Loading
/content/journals/adctra/10.2174/0126673371363002250506053414
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test